News

Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing

/in , , /by

Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug Product, […]

Read more

Chime Biologics Bridges Innovation and Collaboration at Europe-China Biotech Business Forum 2024

/in , , /by

Chime Biologics Bridges Innovation and Collaboration at Europe-China Biotech Business Forum 2024 November 4, Stockholm, Sweden – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, bridged Europe-Asia Biotech innovation and collaboration at the Europe-China Biotech Business Forum 2024, a BIO-Europe side event. Bringing together senior pharmaceutical leaders to explore cross-border […]

Read more

Chime Biologics and Korean Listed Company MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing

/in , , /by

Chime Biologics and Korean Listed Company MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing October 28, 2024, Shanghai, China – Chime Biologics, a leading global CDMO that enables its partners’success in biologics, today announced a strategic collaboration with MedPacto, a South Korean clinically staged company listed on KOSDAQ (235980). MedPacto, known for […]

Read more

Chime Biologics congratulates Hope Medicine on HMI-115’s CDE Breakthrough Therapy Designation

/in , /by

Chime Biologics congratulates Hope Medicine on HMI-115’s CDE Breakthrough Therapy Designation Not available.

Read more

Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics

/in , /by

Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics SEATTLE, Oct. 9, 2024 /PRNewswire/ — Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bispecific T-cell engagers (TCEs) and antibody-drug conjugates […]

Read more

Chime Biologics Successfully Hosts Fuel BioGrowth Chime Day 2024 Event

/in , /by

Chime Biologics Successfully Hosts Fuel BioGrowth Chime Day 2024 Event September 30, 2024, Wuhan – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, successfully hosted the “Fuel BioGrowth Chime Day” event on September 27 at the East Lake Hotel in Wuhan. The event gathered top key opinion leaders (KOLs) and […]

Read more

Chime Biologics won two awards at the Asia Pacific Biologics CMO Excellence Awards 2024

/in /by

Chime Biologics won two awards at the Asia Pacific Biologics CMO Excellence Awards 2024 Recently, at the 3rd Biologics Contract Manufacturing Asia held in Singapore, Chime Biologics was honored with two prestigious awards at the Asia Pacific Biologics CMO Excellence Awards (APBCEA) 2024 — “Best CDMO Award of the Year” and “Best Biologics CMO Award: […]

Read more

pilot-plant-of-chime-biologics

/in , /by

 pilot-plant-of-chime-biologics No content available

Read more

Going Global – Chime Biologics Embraces Innovation and Quality with Partners

/in , /by

Going Global-Chime Biologics Embraces Innovation and Quality with Partners Foreign biopharmaceutical companies seek CDMO partners with long-term prospects, technology levels, and quality systems aligned with international standards. Jimmy Wei, President of Chime Biologics, highlighted that the company’s competitive edge arises from ensuring product quality, leveraging efficiencies, and maintaining stringent cost controls. July 5, 2024, Shanghai, […]

Read more

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

/1 Comment/in , /by

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy The agreement combines Domain Therapeutics’ candidate DT-7012 with Chime Biologics’ internationally-recognized manufacturing expertise In June 2023, Domain nominated DT-7012, a Treg depleting anti-CCR8 monoclonal antibody (mAb) with best-in-class potential, which enters Phase I studies in 2025 The CCR8 GPCR […]

Read more
categoryidArraymk-test